Statistically significant and clinically meaningful reduction in the risk of death seen with Blenrep (belantamab mafodotin) plus bortezomib and dexamethasone (BorDex) versus daratumumab plus BorDex
Opinion granted based on positive overall survival results from the IND.227/KEYNOTE-483 trial
We are witnessing a steady and sustainable growth in the country as the Q2 revenue from operations increased by 31%
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
The FDA conducted a comprehensive Pre-Approval Inspection (PAI) and cGMP audit
Hospital business revenues increase 13.9% to Rs. 1,655 crore
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
US Generics grew 5% to Rs. 467 Crores for the quarter
Raises 2024 revenue guidance to a range of US$ 61 to US$ 64 billion
Subscribe To Our Newsletter & Stay Updated
